Nebenwirkungen · Nubeqa
NUBEQA 300 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 7
HOS-142099 · Präparat HOS-098752
site conditions Investigationsf Neutrophil count decreased Blood bilirubin increased ALT increased AST increased a The median duration of exposure in the ARAMIS and ARANOTE studies was 18.2 months (range: 0.0 to 44.3 months) in patients treated with darolutamide and 11.6 months (range: 0.0 to 40.5 months) in patients treated with placebo. b Includes arteriosclerosis coronary artery, coronary artery disease, coronary artery occlusion, coronary artery stenosis, acute coronary syndrome, acute myocardial infarction, angina pectoris, angina unstable, myocardial infarction, myocardial ischaemia. c Includes cardiac failure, cardiac failure acute, cardiac failure chronic, cardiac failure congestive, cardiogenic shock, heart failure with preserved ejection fraction. d Includes rash, rash macular, rash maculo-papular, rash papular, rash pustular, erythema, dermatitis. e Includes fatigue and asthenia, lethargy and malaise.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-21T11:00:00Z · SHA-256 da13d7ad15d93e78a0008f5eb25e09dc0942552321540cdc62987578c964dccb · Passage f464aea39f191a0fdace0db8eaeacd246edd76fefc05b936905db5872a83f335 · Zeichen 1903–3047 im Abschnitt